The DEA Removes CBD From the Controlled Substances Act –

New Post Public Reply Private Reply Replies (0) Message Board
Kgem
245
The DEA Removes CBD From the Controlled Substances Act – But There’s A Catch


Earlier this month, a well-known drug manufacturer received word that a CBD-based medication will no longer be regulated under the United States Controlled Substances Act.

Epidiolex, a medication made with CBD that is used to treat certain types of epilepsy, will now be marketed as a normal medication. While this is fantastic news, it’s also a bit confusing since CBD is already federally legal. While this announcement effectively removes CBD from the controlled substances act, much remains to be understood about how the U.S. regulates cannabidiol.

The Initial Announcement

On Monday, April 6, GW Pharmaceuticals announced that the company had received notice from the DEA (United States Drug Enforcement Administration) stating that Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”).

According to the statement released by GW CEO Justin Gover, “This notification from DEA fully establishes that EPIDIOLEX, the only CBD medicine approved by FDA, is no longer a controlled substance under the federal Controlled Substances Act. We would like to thank DEA for confirming the non-controlled status of this medicine. Importantly, the descheduling of EPIDIOLEX has the potential to further ease patient access to this important therapy for patients living with Lennox-Gastaut Syndrome and Dravet syndrome.”

Epidiolex first launched in the United States in late 2018 and has since formed a market in 30 European countries and is currently undergoing clinical testing in Japan. It’s the first and only CBD-based drug to be approved by the FDA (United States Food and Drug Administration). This medication is used to treat the two aforementioned forms of epilepsy (Lennox-Gastaut Syndrome and Dravet syndrome), which are both extremely rare, severe, and debilitating.

Keep in mind that all non-Epidiolex CBD products are still illegal and will be regulated under the FDA Controlled Substances Act. The FDA has recently cemented their position on CBD, stating that cannabidiol’s safety profile has “not been established” and that and products containing the compound will be viewed as “adulterated and misbranded drugs.”

Confusing and Contradictory Laws

The FDA’s clarified stance on CBD is extremely contradictory, especially after they released a 27-page report nearly 2 years ago in which FDA officials argued (rather convincingly I might add), that CBD-use is associated with a very low risk profile.

From the report, “Upon consideration of the eight factors determinative of control of a substance under section 201 (c) of the CSA, FDA concludes that CBD and its salts … could be removed from under the CSA… We reach this conclusion because we find that CBD does not meet the criteria for placement in and of Schedules II, III, IV, or V under the CSA.”

That said, GW is wasting no time in updating their facilities and operations throughout their distribution network. They will be look at this on a state-by-state basis and will begin shipping Epidiolex to pharmacies and will possibly even have access to prescription delivery though some insurance networks. The doors are certainly open wider for the drug manufacturer now.

So, Is CBD Legal or Not?

Honestly, it’s still all very confusing. Simply put, it’s legal but highly regulated. To expand on that a little bit, we’ll have to take a look at the 2018 Farm Bill that legalized hemp at the federal level and removed it from the controlled substances act. But what is defined as hemp?

According to the FDA, hemp is defined as “the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis.”

Hemp, both industrial and smokable CBD Flowers, are NOT regulated as controlled substances. However, any manufactured product containing cannabis or hemp extracts (ie – cannabinoids) still is. That means CBD-infused supplements, medications, edibles, and cosmetics are still technically illegal unless they have been subjected to FDA-approval, which is a tedious and costly endeavor.

This will remain the same, the only difference is that now, Epidiolex can be manufactured and sold as non-controlled substance. In the United States, most medications such as those for blood pressure, diabetes, heart conditions, and other common illnesses are not considered “controlled substances”. Medications that can cause mental and physical dependence, like pain medications for example, are regulated under the controlled subsantces act because there are restrictions on the way these prescriptions can be filled and refilled.

The Silver Lining

Even though this change only applies to Epidiolex, it goes without saying that it’s a testament to the effectiveness of CBD-based therapies. The FDA and DEA have both officially acknowledged that, yes, CBD can be used safely to treat certain health conditions.

Additionally, loosening restrictions on the way these prescriptions are filled means that patients will have easier access to this medication. It will be easier to obtain and likely cheaper. When a medication is regulated as a controlled substance, there are certain requirements that are needed to fill and refill these prescriptions. Patients will need to be a certain age, will need to have an ID, and the amount of controlled-medications that can be prescribed each month is limited.

People will still need to get a prescription from a licensed physician, but the prescription will be valid for a year, it can be transferred between pharmacies, and state reporting requirements will no longer apply.

Final Thoughts

Having CBD removed from the controlled substances act is a big deal. Even though it only applies to one medication (for now), it’s a step in the right direction. Things are at a bit of stand-still in most industries right now, but as more cannabis-medications go through clinical testing, there will be an influx of these easy-to-access CBD therapies on the market.


Source: 420intel.com




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Differentia Bio's AI: Transforming Drug Development Dynamics

Updated Category News Views 51

The Future of Drug Development: AI's New Role When it comes to pharmaceutical R&D, Some outfits are playing pin the tail on the donkey, but Differentia Bio over here is sharpening the pin with some futuristic gadgetry. Yep, they're jazzing up the game with AI-powered digital twins, building lifelike disease environments that predict therapeutic outcomes with precision...

Continue Reading
Grupo Bimbo Climbs Rankings as Top Global Employer

Updated Category News Views 151

Grupo Bimbo’s Big Leap on the Global Stage Cranking out a solid rise in reputation, Grupo Bimbo has jumped up 107 positions to seize the 444th spot in the 2026 Forbes 'World's Best Employers' list. This isn't just a one-off headline-grabber; it's a testament to the serious work going on behind the scenes at this baking giant. Clawing its way higher from rank 551 in the...

Continue Reading
Edible Oils: Market Growth, Trends, and Investments

Updated Category News Views 90

Riding the Edible Oil Wave The edible oils market seems to be gearing up for a steady rise. Folks, the numbers are speaking loud and clear. We're looking at the market booming from USD 277.74 billion in 2026 to a hefty USD 351.08 billion in 2031. According to MarketsandMarkets™, a compound annual growth rate (CAGR) of 4.8% is on the cards. Now, if that doesn't get the...

Continue Reading
Canton Fair Showcases Cutting-Edge Healthcare Tech 2026

Updated Category News Views 41

Innovation Steals the Show in Guangzhou In a world where tech evolution rarely takes a breather, the 140th Canton Fair's Intelligent Healthcare Zone is like a breath of fresh air. Picture it: a whole arena pulsing with futuristic healthcare gizmos from October 31 to November 4, 2026—it's as if tomorrow swung by for a sneak peek. The event brings together everything from...

Continue Reading
Cathy Craig Drives $163M in Broken Bow Airbnb Deals

Updated Category News Views 56

Investors Find Gold in Broken Bow’s Airbnb Market When did Broken Bow, Oklahoma, become the go-to spot for adventurous investors looking to park their cash in timberland sanctuary cabins? Well, Cathy Craig seems to know the secret sauce, having navigated over $163 million worth of Airbnb and VRBO cabin deals for her clients since 2021. Her knack for spotting cabins that...

Continue Reading
i-80 Gold's Q3 2026: Production Plans Unveiled

Updated Category News Views 62

Gold Miners on the Move: Eye on i-80 Wake up and smell the gold, folks. i-80 Gold is ramping up to increase its yearly gold production targets, aiming for a hefty 150,000 to 200,000 ounces by 2028. Now, if you’ve been around the block like me, you know these are the kind of numbers that get investors either shifting in their chairs or springing to their feet. A Brief...

Continue Reading
XPLR Infrastructure Posts Solid Q3 Results, Eyes Growth

Updated Category News Views 65

Third Quarter Results: Crunching the Numbers Every season brings new tidbits, and when XPLR Infrastructure, LP (NYSE: XIFR) dropped their third-quarter 2026 results, you bet I was ready with my magnifying glass. November 3rd was the day to circle on your calendars, as the folks over at Juno Beach sure had something to say. They’ve plastered the details across their...

Continue Reading
Waters Acquires MOBILion: Ion Mobility Meets AI

Updated Category News Views 18

MOBILion Joins Waters' Fold: A New Era for Proteomics Ah, the biotech world just saw another big whirl with Waters Corporation snagging MOBILion Systems. Now, this isn't just some stroll in the market park. We're talking about weaving MOBILion's fancy high-resolution ion mobility separation tech right into Waters' already robust mass spectrometry setup. These folks are...

Continue Reading
Maya Mobile Wins Best Global Roaming Services 2026

Updated Category News Views 112

Travelers Speak: Maya Tops Global Roaming It's not every day that you see the travel community collectively high-five a company, but that's precisely what happened with Maya Mobile. These folks just snagged the Best Global Roaming Services title at the TripZilla Excellence Awards 2026, and it's not just fluff—it's voted by travelers. This ain't your typical pat on the...

Continue Reading
Massimo Debuts 1500 UTV Line at 2026 SEMA Show

Updated Category News Views 58

Setting the Stage at SEMA 2026 In the chaotic whirl of the 2026 SEMA Show, Massimo Group didn't just roll out new wheels—they took a leap into the big leagues. Amidst the bustling Vegas crowd, Massimo unveiled their latest babies: the Warrior 1500XD and the Sentinel 1500 HVAC Crew. These ain't just any UTVs; they're packing some serious muscle with a 1,499cc engine,...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Non-Thermal Pasteurization: A Market Overview

Updated Category News Views 148

Growth Prospects for the Non-Thermal Pasteurization Market The non-thermal pasteurization market is on an impressive growth trajectory, with expectations to expand from USD 2.3 billion in 2023 to USD 5.7 billion by 2028. This remarkable increase signifies a compound annual growth rate (CAGR) of 20.0%, showcasing the rising popularity of innovative pasteurization...

Continue Reading
Exploring SI-BONE's Promising Financial Future and Growth Potential

Updated Category News Views 82

SI-BONE, Inc. (NASDAQ:SIBN) stood out as a player in the medical device sector back then, focusing on surgical solutions for musculoskeletal disorders of the sacropelvic anatomy. They reported worldwide revenues hitting $40 million—a 20% leap from previous figures—outdoing analysts who pegged expectations at $39.1 million. But here’s the kicker: while revenue looks...

Continue Reading
Explore the Future of IoT Development with Silicon Labs Innovation

Updated Category News Views 237

Revolutionizing IoT Development with the Simplicity Ecosystem Today, developers are provided with the tools for faster and more intelligent workflows, thanks to the launch of the Simplicity Ecosystem by Silicon Labs (NASDAQ: SLAB). This innovative suite introduces a new era in embedded IoT development by integrating advanced AI capabilities within its modular software...

Continue Reading
CME Group Hits Record Volume: Midyear Surge in 2026

Updated Category News Views 16

CME Group's Volume Surge: A Record-setting Performance When it comes to trading, sometimes the numbers speak louder than words. CME Group, the behemoth of derivatives trading, has smashed through its own ceilings. June 2026 saw an average daily volume (ADV) of 30.6 million contracts, the highest for any June ever. Add to that their second-best Q2 with 29.8 million...

Continue Reading
Talisker Reports High-Grade Gold Assays from Mustang Mine

Updated Category News Views 184

Talisker Reports Promising Assay Results from Mustang Mine Toronto — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQX: TSKFF) has announced exciting assay results stemming from its underground face sampling of the 1060 level lateral development at the Mustang Mine. Following previous press releases detailing findings from the higher 1075...

Continue Reading